|
1
|
Tao J, Zhi X, Zhang X, Fu M, Huang H, Fan
Y, Guan W and Zou C: miR-27b-3p suppresses cell proliferation
through targeting receptor tyrosine kinase like orphan receptor 1
in gastric cancer. J Exp Clin Cancer Res. 34:1392015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee YY and Derakhshan MH: Environmental
and lifestyle risk factors of gastric cancer. Arch Iran Med.
16:358–365. 2013.PubMed/NCBI
|
|
4
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng XJ, Lin JC and Tu SP: Etiology and
prevention of gastric cancer. Gastrointest Tumors. 3:25–36. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pennathur A, Farkas A, Krasinskas AM,
Ferson PF, Gooding WE, Gibson MK, Schuchert MJ, Landreneau RJ and
Luketich JD: Esophagectomy for T1 esophageal cancer: Outcomes in
100 patients and implications for endoscopic therapy. Ann Thorac
Surg. 87:1048–1055. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
GASTRIC (Global Advanced/Adjuvant Stomach
Tumor Research International Collaboration) Group, ; Paoletti X,
Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P,
Sakamoto J, Sargent D, et al: Benefit of adjuvant chemotherapy for
resectable gastric cancer: A meta-analysis. JAMA. 303:1729–1737.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ahn JY, Hwang HS, Park YS, Kim HR, Jung
HY, Kim JH, Lee SE and Kim MA: Endoscopic and pathologic findings
associated with clinical outcomes of melanoma in the upper
gastrointestinal tract. Ann Surg Oncol. 21:2532–2539. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Smith A, Simanski S, Fallahi M and Ayad
NG: Redundant ubiquitin ligase activities regulate wee1 degradation
and mitotic entry. Cell Cycle. 6:2795–2759. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshida K: Cell-cycle-dependent regulation
of the human and mouse Tome-1 promoters. FEBS Lett. 579:1488–1492.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lim HH and Surana U: Tome-1, wee1, and the
onset of mitosis: Coupled destruction for timely entry. Mol Cell.
11:845–546. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim YJ and Bahk YY: A study of substrate
specificity for a CTD phosphatase, SCP1, by proteomic screening of
binding partners. Biochem Biophys Res Commun. 448:189–194. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng N, Schulman BA, Song L, Miller JJ,
Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, et al:
Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin
ligase complex. Nature. 416:703–709. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Itzel T, Scholz P, Maass T, Krupp M,
Marquardt JU, Strand S, Becker D, Staib F, Binder H, Roessler S, et
al: Translating bioinformatics in oncology: Guilt-by-profiling
analysis and identification of KIF18B and CDCA3 as novel driver
genes in carcinogenesis. Bioinformatics. 31:216–224. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Adams MN, Burgess JT, He Y, Gately K,
Snell C, Zhang SD, Hooper JD, Richard DJ and O'Byrne KJ: Expression
of CDCA3 is a prognostic biomarker and potential therapeutic target
in non-small cell lung cancer. J Thorac Oncol. 12:1071–1084. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen J, Zhu S, Jiang N, Shang Z, Quan C
and Niu Y: HoxB3 promotes prostate cancer cell progression by
transactivating CDCA3. Cancer Lett. 330:217–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu Q, Fu J, Luo B, Huang M, Guo W, Lin Y,
Xie X and Xiao S: OY-TES-1 may regulate the malignant behavior of
liver cancer via NANOG, CD9, CCND2 and CDCA3: A bioinformatic
analysis combine with RNAi and oligonucleotide microarray. Oncol
Rep. 33:1965–1975. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pérez-Peña J, Alcaraz-Sanabria A,
Nieto-Jiménez C, Páez R, Corrales-Sánchez V, Serrano-Oviedo L, Wali
VB, Patwardhan GA, Amir E, Győrffy B, et al: Mitotic read-out genes
confer poor outcome in luminal A breast cancer tumors. Oncotarget.
8:21733–21740. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Uchida F, Uzawa K, Kasamatsu A, Takatori
H, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H and Bukawa H:
Overexpression of cell cycle regulator CDCA3 promotes oral cancer
progression by enhancing cell proliferation with prevention of G1
phase arrest. BMC Cancer. 12:3212012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
O'Byrne K, Adams M, Burgess J and Richard
D: 24P CDCA3 regulates the cell cycle and modulates cisplatin
sensitivity in non-small cell lung cancer. J Thorac Oncol. 11
(Suppl):S652016. View Article : Google Scholar
|
|
22
|
Su P, Wen S, Zhang Y, Li Y, Xu Y, Zhu Y,
Lv H, Zhang F, Wang M and Tian Z: Identification of the key genes
and pathways in esophageal carcinoma. Gastroenterol Res Pract.
2016:29681062016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou J and Hsieh JT: The inhibitory role
of DOC- 2/DAB2 in growth factor receptor-mediated signal cascade.
DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding
to Grb2. J Biol Chem. 276:27793–27798. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang Z, Tseng CP, Pong RC, Chen H,
McConnell JD, Navone N and Hsieh JT: The mechanism of
growth-inhibitory effect of DOC-2/DAB2 in prostate cancer.
Characterization of a novel GTPase-activating protein associated
with N-terminal domain of DOC-2/DAB2. J Biol Chem. 277:12622–12631.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen H, Pong RC, Wang Z and Hsieh JT:
Differential regulation of the human gene DAB2IP in normal
and malignant prostatic epithelia: Cloning and characterization.
Genomics. 79:573–581. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu K, Liu J, Tseng SF, Gore C, Ning Z,
Sharifi N, Fazli L, Gleave M, Kapur P, Xiao G, et al: The role of
DAB2IP in androgen receptor activation during prostate cancer
progression. Oncogene. 33:1954–1963. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Valentino E, Bellazzo A, Di Minin G,
Sicari D, Apollonio M, Scognamiglio G, Di Bonito M, Botti G, Del
Sal G and Collavin L: Mutant p53 potentiates the oncogenic effects
of insulin by inhibiting the tumor suppressor DAB2IP. Proc Natl
Acad Sci USA. 114:7623–7628. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ren G, Baritaki S, Marathe H, Feng J, Park
S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, et al:
Polycomb protein EZH2 regulates tumor invasion via the
transcriptional repression of the metastasis suppressor RKIP in
breast and prostate cancer. Cancer Res. 72:3091–3104. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hsieh JT, Karam JA and Min W: Genetic and
biologic evidence that implicates a gene in aggressive prostate
cancer. J Natl Cancer Inst. 99:1823–1824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dote H, Toyooka S, Tsukuda K, Yano M,
Ouchida M, Doihara H, Suzuki M, Chen H, Hsieh JT, Gazdar AF and
Shimizu N: Aberrant promoter methylation in human DAB2 interactive
protein (hDAB2IP) gene in breast cancer. Clin Cancer Res.
10:2082–2089. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie D, Gore C, Liu J, Pong RC, Mason R,
Hao G, Long M, Kabbani W, Yu L, Zhang H, et al: Role of DAB2IP in
modulating epithelial-to-mesenchymal transition and prostate cancer
metastasis. Proc Natl Acad Sci USA. 107:2485–2490. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xie D, Gore C, Zhou J, Pong RC, Zhang H,
Yu L, Vessella RL, Min W and Hsieh JT: DAB2IP coordinates both
PI3K-Akt and ASK1 pathways for cell survival and apoptosis. Proc
Natl Acad Sci USA. 106:19878–19883. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ryan MB, Finn AJ, Pedone KH, Thomas NE,
Der CJ and Cox AD: ERK/MAPK signaling drives overexpression of the
Rac-GEF, PREX1, in BRAF- and NRAS-mutant melanoma. Mol Cancer Res.
14:1009–1018. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vial E, Sahai E and Marshall CJ: ERK-MAPK
signaling coordinately regulates activity of Rac1 and RhoA for
tumor cell motility. Cancer Cell. 4:67–79. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Widmann C, Gibson S, Jarpe MB and Johnson
GL: Mitogen-activated protein kinase: Conservation of a
three-kinase module from yeast to human. Physiol Rev. 79:143–180.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Robinson MJ and Cobb MH: Mitogen-activated
protein kinase pathways. Curr Opin Cell Biol. 9:180–186. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Datta A, Kim H, Lal M, McGee L, Johnson A,
Moustafa AA, Jones JC, Mondal D, Ferrer M and Abdel-Mageed AB:
Manumycin A suppresses exosome biogenesis and secretion via
targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in
castration-resistant prostate cancer cells. Cancer Lett. 408:73–81.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang X, Liu G, Ding L, Jiang T, Shao S,
Gao Y and Lu Y: HOXA3 promotes tumor growth of human colon cancer
through activating EGFR/Ras/Raf/MEK/ERK signaling pathway. J Cell
Biochem. 119:2864–2874. 2018. View Article : Google Scholar : PubMed/NCBI
|
